ImmunePharma

Immune Pharmaceuticals (OTCQB: $IMNP) is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.

[ImmunePharma @ImmunePharma]

$IMNP has engaged Extera Partners to lead the Company’s ongoing effort to secure a partnership for bertilimumab, a phase 2, first-in-class, fully human anti-eotaxin-1 monoclonal antibody https://t.co/VW4wPyMg5J

[ImmunePharma @ImmunePharma]

Immune grants Vector Therapeutics exclusive option to acquire worldwide Ceplene rights. Learn more here: https://t.co/Uyxw8BxZM1

[ImmunePharma @ImmunePharma]

To participate in today's update conference call at 8:30 am ET please dial 877-407-9122 (domestic) or 201-493-6747 (international) or access a webcast here: https://t.co/bv364XPtp7 $IMNP

[ImmunePharma @ImmunePharma]

Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights https://t.co/kbUfjYmk2l $IMNP

[ImmunePharma @ImmunePharma]

Immune is delaying its corporate call until after the holiday week in order to provide a more comprehensive shareholder update. The call will now take place on Tuesday, November 27 at 8:30 am ET. For conference call details, click here: https://t.co/BiwE9kzi2X $IMNP

[ImmunePharma @ImmunePharma]

Immune Pharmaceuticals Reschedules Corporate Update Call https://t.co/MonwXJEvLZ $IMNP

[ImmunePharma @ImmunePharma]

$IMNP interim CEO will provide an update on various corporate matters, including the bertilimumab clinical development program, the company’s finances, and the forthcoming special meeting of stockholders, scheduled for 10/5 on in a conference call on 11/20 https://t.co/assfrNQUJz

[ImmunePharma @ImmunePharma]

$IMNP will provide a corporate update on Tuesday, November 20 at 8:30 am ET. Conference call and webcast details available here: https://t.co/assfrNQUJz

[ImmunePharma @ImmunePharma]

The mean serum concentration of autoantibodies to BP180 (type 17 collagen) declined over the course of a phase 2a study of bertilimumab in elderly #BullousPemphigoid patients https://t.co/Fvu3BcpREu $IMNP

[ImmunePharma @ImmunePharma]

The PK profile of bertilimumab in elderly #BullousPemphigoid patients is similar to the profile observed in young, healthy volunteers and supports a once every two week dosing regimen https://t.co/Fvu3BcpREu $IMNP

[ImmunePharma @ImmunePharma]

No anti-drug antibodies were observed in any subject at any timepoint in our phase 2a study of bertilimumab in #BullousPemphigoid https://t.co/Fvu3BcpREu $IMNP

[ImmunePharma @ImmunePharma]

$IMNP today released additional results from its positive, proof-of-concept phase 2a trial of bertilimumab in #BullousPemphigoid https://t.co/Fvu3BcpREu

[ImmunePharma @ImmunePharma]

$IMNP CEO comments on preclinical asthma results and the potential of bertilimumab to have a broader anti-inflammatory effect in human asthma than the IL-5-targeting agents https://t.co/C9LvBypVt9

[ImmunePharma @ImmunePharma]

In a mouse model of asthma, eotaxin-1 blockade had an unexpectedly broad effect on all inflammatory cells, including not only eosinophils, but neutrophils, macrophages and lymphocytes as well https://t.co/C9LvBypVt9 $IMNP

[ImmunePharma @ImmunePharma]

Results from a mouse study demonstrated that blockade of eotaxin-1 reduces lung inflammation and has a broader inhibitory effect on inflammatory cells than does blockade of interleukin (IL)-5 https://t.co/C9LvBypVt9 $IMNP

[ImmunePharma @ImmunePharma]

$IMNP announced positive preclinical results in asthma demonstrating broad anti-inflammatory effects https://t.co/C9LvBypVt9

[ImmunePharma @ImmunePharma]

Immune Pharmaceuticals Announces $5 Million Financing https://t.co/yhLrEoPPYG

[ImmunePharma @ImmunePharma]

To participate in today's update conference call at 8:30 a.m. EDT, please dial 877-407-9122 (domestic) or 201-493-6747 (international) or access a live webcast here: https://t.co/qltLC4zvPt

[ImmunePharma @ImmunePharma]

Immune Pharmaceuticals Provides a Corporate Update https://t.co/XV7zwPoj4Z $IMNP

[ImmunePharma @ImmunePharma]

$IMNP received Fast Track designation for bertilimumab which enables more frequent interactions w/ the FDA in order to shorten the development & review process, & may include potential eligibility for Accelerated Approval, Priority Review & Rolling Review https://t.co/TXoohphWLn